Catalyst Pharmaceuticals Inc (CPRX)
Debt-to-equity ratio
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Long-term debt | US$ in thousands | — | — | — | — | — |
| Total stockholders’ equity | US$ in thousands | 727,632 | 387,881 | 300,421 | 206,831 | 169,598 |
| Debt-to-equity ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
December 31, 2024 calculation
Debt-to-equity ratio = Long-term debt ÷ Total stockholders’ equity
= $—K ÷ $727,632K
= 0.00
Based on the data provided, Catalyst Pharmaceuticals Inc has consistently maintained a debt-to-equity ratio of 0.00 from December 31, 2020, to December 31, 2024. A debt-to-equity ratio of 0.00 indicates that the company has no debt or negligible debt compared to its equity, implying that the company primarily relies on equity financing to fund its operations. This suggests a low financial risk as the absence of debt means that the company is not heavily leveraged and may have a strong financial position with a lower probability of default. Additionally, a low debt-to-equity ratio can be positive in terms of financial flexibility and can potentially signal stability to investors and creditors.
Peer comparison
Dec 31, 2024